ProCE Banner Activity

FINCH 3: Phase III Trial of Filgotinib ± Methotrexate in Methotrexate-Naive Patients With Rheumatoid Arthritis

Slideset Download
Conference Coverage
Addition of JAK1 inhibitor to methotrexate improved ACR20 responses compared with methotrexate alone in methotrexate-naive patients with RA.

Released: June 27, 2019

Expiration: June 25, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Lilly

Sanofi Genzyme and Regeneron Pharmaceuticals